Merck Serono Biosimilars Head Thierry Hulot On Minimizing Risks And Upfront Costs: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Merck Serono is hopeful of capitalizing on the gaps existing in access for lifesaving oncology biosimilars